Promotion of lung tumor growth by interleukin-17

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 307, Issue 6, 2014, Pages L497-L508

  Xu, Beibei ^a   Guenther, James F ^a   Pociask, Derek A ^b   Wang, Y ^a   Kolls, Jay K ^b   Zongbing, You ^a   Chandrasekar, Bysani ^a   Shan, Bin ^a   Sullivan, Deborah E ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

IL 17; Lung tumor growth; MMP 9; p53; SRSF1

Indexed keywords

CIGARETTE SMOKE; GELATINASE A; GELATINASE B; GREEN FLUORESCENT PROTEIN; INTERLEUKIN 17; K RAS PROTEIN; MATRIX METALLOPROTEINASE 14; PROTEIN P53; SERINE ARGININE RICH SPLICING FACTOR; IL17A PROTEIN, HUMAN; IL17A PROTEIN, MOUSE; KRAS2 PROTEIN, MOUSE; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, MOUSE; NUCLEAR PROTEIN; PROTEIN P21; RNA BINDING PROTEIN; SERINE ARGININE RICH SPLICING PROTEINS; SERINE-ARGININE-RICH SPLICING PROTEINS; SPERMATOGENESIS RELATED SPLICING FACTOR, MOUSE; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL VIABILITY; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM CELL; LUNG LAVAGE; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TH17 CELL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; CELL MOTION; ENZYME STABILITY; GENE SILENCING; GENETICS; HUMAN; LUNG TUMOR GROWTH; METABOLISM; MMP-9; PATHOLOGY; SRSF1; TRANSGENIC MOUSE; TUMOR INVASION;

IL-17; LUNG TUMOR GROWTH; MMP-9; P53; SRSF1;

ANIMALS; CELL MOVEMENT; ENZYME STABILITY; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-17; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RNA-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84908511579     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00125.2014     Document Type: Article

References (80)

1. Benevides L, Cardoso CR, Tiezzi DG, Marana HR, Andrade JM, Silva JS. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol 43: 1518–1528, 2013.
2. Chang CK, Hung WC, Chang HC. The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med 12: 2781–2789, 2008.
3. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA 111: 5664–5669, 2014.
4. Chen K, Pociask DA, McAleer JP, Chan YR, Alcorn JF, Kreindler JL, Keyser MR, Shapiro SD, Houghton AM, Kolls JK, Zheng M. IL-17RA is required for CCL2 expression, macrophage recruitment, and emphysema in response to cigarette smoke. PLoS One 6: e20333, 2011.
5. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387–2392, 2002.
6. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, Cruz-Monser-rate Z, Wang H, Ji B, Logsdon CD. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest 122: 1519–1528, 2012.
7. Diament MJ, Peluffo GD, Stillitani I, Cerchietti LC, Navigante A, Ranuncolo SM, Klein SM. Inhibition of tumor progression and paraneo-plastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer Invest 24: 126–131, 2006.
8. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174, 2002.
9. Ertan E, Soydinc H, Yazar A, Ustuner Z, Tas F, Yasasever V. Matrix metalloproteinase-9 decreased after chemotherapy in patients with non-small cell lung cancer. Tumori 97: 286–289, 2011.
10. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 26: 1268–1286, 2012.
11. Fregoso OI, Das S, Akerman M, Krainer AR. Splicing-factor oncopro-tein SRSF1 stabilizes p53 via RPL5 and induces cellular senescence. Mol Cell 50: 56–66, 2013.
12. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12: 298–306, 2012.
13. Friedlander PL, Delaune CL, Abadie JM, Toups M, LaCour J, Marrero L, Zhong Q, Kolls JK. Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol 29: 321–330, 2003.
14. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 9: 556–567, 2009.
15. Gong Y, Hart E, Shchurin A, Hoover-Plow J. Inflammatory macro-phage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 118: 3012–3024, 2008.
16. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D, Taniguchi K, Yu GY, Osterreicher CH, Hung KE, Datz C, Feng Y, Fearon ER, Oukka M, Tessarollo L, Coppola V, Yarovinsky F, Cheroutre H, Eckmann L, Trinchieri G, Karin M. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491: 254–258, 2012.
17. Guenther JF, Cameron JE, Nguyen HT, Wang Y, Sullivan DE, Shan B, Lasky JA, Flemington EK, Morris GF. Modulation of lung inflammation by the Epstein-Barr virus protein Zta. Am J Physiol Lung Cell Mol Physiol 299: L771–L784, 2010.
18. Hemdan NY. Anti-cancer vs. cancer-promoting effects of the interleukin-17-producing T helper cells. Immunol Lett 149: 123–133, 2013.
19. Herjan T, Yao P, Qian W, Li X, Liu C, Bulek K, Sun D, Yang WP, Zhu J, He A, Carman JA, Erzurum SC, Lipshitz HD, Fox PL, Hamilton TA. HuR is required for IL-17-induced Act1-mediated CXCL1 and CXCL5 mRNA stabilization. J Immunol 191: 640–649, 2013.
20. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley JM, Senior RM, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2: 289–300, 2002.
21. Houghton AM.. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13: 233–245, 2013.
22. Houghton AM. The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle 9: 1732–1737, 2010.
23. Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, Stolz DB, Land SR, Marconcini LA, Kliment CR, Jenkins KM, Beaulieu KA, Mouded M, Frank SJ, Wong KK, Shapiro SD. Neutro-phil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 16: 219–223, 2010.
24. Hu Y, Ota N, Peng I, Refino CJ, Danilenko DM, Caplazi P, Ouyang W. IL-17RC is required for IL-17A- and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis. J Immunol 184: 4307–4316, 2010.
25. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 65: 10280–10288, 2005.
26. Kao SJ, Su JL, Chen CK, Yu MC, Bai KJ, Chang JH, Bien MY, Yang SF, Chien MH. Osthole inhibits the invasive ability of human lung adenocar-cinoma cells via suppression of NF-kappaB-mediated matrix metallopro-teinase-9 expression. Toxicol Appl Pharmacol 261: 105–115, 2012.
27. Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Res 72: 5576–5587, 2012.
28. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 21: 467–476, 2004.
29. Kryczek I, Wei S, Szeliga W, Vatan L, Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357–359, 2009.
30. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, Harder B, Okada S, Ostrander CD, Kreindler JL, Aujla SJ, Reardon B, Moore M, Shea P, Schreckhise R, Bukowski TR, Presnell S, Guerra-Lewis P, Parrish-Novak J, Ellsworth JL, Jaspers S, Lewis KE, Appleby M, Kolls JK, Rixon M, West JW, Gao Z, Levin SD. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol 179: 5462–5473, 2007.
31. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, Niestroy A, Dahlmann N, Peters A, Berger J, Fiedler W, Hossfeld DK. Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13: 1550–1557, 2002.
32. Lakatos HF, Burgess HA, Thatcher TH, Redonnet MR, Hernady E, Williams JP, Sime PJ. Oropharyngeal aspiration of a silica suspension produces a superior model of silicosis in the mouse compared with intratracheal instillation. Exp Lung Res 32: 181–199, 2006.
33. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, El-Naggar AK, Lozano G. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861–872, 2004.
34. Le Gouvello S, Bastuji-Garin S, Aloulou N, Mansour H, Chaumette MT, Berrehar F, Seikour A, Charachon A, Karoui M, Leroy K, Farcet JP, Sobhani I. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57: 772–779, 2008.
35. Li C, Nguyen HT, Zhuang Y, Lin Y, Flemington EK, Guo W, Guenther J, Burow ME, Morris GF, Sullivan D, Shan B. Post-transcriptional up-regulation of miR-21 by type I collagen. Mol Carcinog 50: 563–570, 2011.
36. Li J, Lau GK, Chen L, Dong SS, Lan HY, Huang XR, Li Y, Luk JM, Yuan YF, Guan XY. Interleukin 17A promotes hepatocellular carcinoma metastasis via NF-kB induced matrix metalloproteinases 2 and 9 expression. PLoS One 6: e21816, 2011.
37. Li Q, Han Y, Fei G, Guo Z, Ren T, Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol Lett 148: 144–150, 2012.
38. Li Y, Cao ZY, Sun B, Wang GY, Fu Z, Liu YM, Kong QF, Wang JH, Zhang Y, Xu XY, Li HL. Effects of IL-17A on the occurrence of lung adenocarcinoma. Cancer Biol Ther 12: 610–616, 2011.
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408, 2001.
40. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 29: 5653–5662, 2010.
41. Martin-Orozco N, Dong C. The IL-17/IL-23 axis of inflammation in cancer: friend or foe? Curr Opin Investig Drugs 10: 543–549, 2009.
42. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 31: 787–798, 2009.
43. Martins SJ, Takagaki TY, Silva AG, Gallo CP, Silva FB, Capelozzi VL. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer 64: 105–109, 2009.
44. McAllister F, Bailey JM, Alsina J, Nirschl CJ, Sharma R, Fan H, Rattigan Y, Roeser JC, Lankapalli RH, Zhang H, Jaffee EM, Drake CG, Housseau F, Maitra A, Kolls JK, Sears CL, Pardoll DM, Leach SD. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell 25: 621–637, 2014.
45. Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462: 104–107, 2009.
46. Minamoto H, Antonangelo L, da Silva AG, Gallo CP, de Andrade e Silva FB, Fenezelian S, Rodrigues OR, Jatene F, Saldiva P, Capelozzi VL. Tumour cell and stromal features in metastatic and non-metastatic non-small cell lung carcinomas. Histopathology 43: 427–443, 2003.
47. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11: 763–776, 2012.
48. Moghaddam SJ, Li H, Cho SN, Dishop MK, Wistuba II, Ji L, Kurie JM, Dickey BF, Demayo FJ. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-in-duced mouse model. Am J Respir Cell Mol Biol 40: 443–453, 2009.
49. Morris GF, Hoyle GW, Athas GB, Lei WH, Xu J, Morris CB, Friedman M. Lung-specific expression in mice of a dominant negative mutant form of the p53 tumor suppressor protein. J La State Med Soc 150: 179–185, 1998.
50. Morris GF, Labrie C, Mathews MB. Modulation of transcriptional activation of the proliferating cell nuclear antigen promoter by the ade-novirus E1A 243-residue oncoprotein depends on proximal activators. Mol Cell Biol 14: 543–553, 1994.
51. Navratilova Z, Zatloukal J, Kriegova E, Kolek V, Petrek M. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease. Respirology 17: 1006–1012, 2012.
52. Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175: 6177–6189, 2005.
53. O’Kane CM, McKeown SW, Perkins GD, Bassford CR, Gao F, Thickett DR, McAuley DF. Salbutamol up-regulates matrix metallopro-teinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 37: 2242–2249, 2009.
54. Oh J, Takahashi R, Kondo S, Mizoguchi A, Adachi E, Sasahara RM, Nishimura S, Imamura Y, Kitayama H, Alexander DB, Ide C, Horan TP, Arakawa T, Yoshida H, Nishikawa S, Itoh Y, Seiki M, Itohara S, Takahashi C, Noda M. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 107: 789–800, 2001.
55. Okamoto T, Valacchi G, Gohil K, Akaike T, van der Vliet A. S-nitrosothiols inhibit cytokine-mediated induction of matrix metalloproteinase-9 in airway epithelial cells. Am J Respir Cell Mol Biol 27: 463–473, 2002.
56. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133–1141, 2005.
57. Reppert S, Boross I, Koslowski M, Tureci O, Koch S, Lehr HA, Finotto S. A role for T-bet-mediated tumour immune surveillance in anti-IL-17A treatment of lung cancer. Nat Commun 2: 600, 2011.
58. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, Nelson S, Bagby GJ, Stoltz D, Mynatt RL, Spriggs M, Kolls JK. IL-17 stimulates granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 161: 6383–6389, 1998.
59. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, Meeker AK, Isaacs WB, Drake CG. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 14: 3254–3261, 2008.
60. Shan B, Morris GF. Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53. Exp Cell Res 305: 10–22, 2005.
61. Shan M, Yuan X, Song LZ, Roberts L, Zarinkamar N, Seryshev A, Zhang Y, Hilsenbeck S, Chang SH, Dong C, Corry DB, Kheradmand F. Cigarette smoke induction of osteopontin (SPP1) mediates TH17 inflammation in human and experimental emphysema. Sci Transl Med 4: 117-119, 2012.
62. Shyamsundar M, McAuley DF, Ingram RJ, Gibson DS, O’Kane D, McKeown ST, Edwards A, Taggart C, Elborn JS, Calfee CS, Matthay MA, O’Kane CM. Keratinocyte growth-factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med 189: 1520–1529, 2014.
63. Siddesha JM, Valente AJ, Sakamuri SS, Yoshida T, Gardner JD, Somanna N, Takahashi C, Noda M, Chandrasekar B. Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK. J Mol Cell Cardiol 65: 9–18, 2013.
64. Sossey-Alaoui K, Ranalli TA, Li X, Bakin AV, Cowell JK. WAVE3 promotes cell motility and invasion through the regulation of MMP-1, MMP-3, and MMP-9 expression. Exp Cell Res 308: 135–145, 2005.
65. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6: 447–458, 2004.
66. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200: 448–464, 2003.
67. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF). Nat Immunol 12: 853–860, 2011.
68. Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, Sato M, Kaira K, Ishizuka T, Gazdar AF, Minna JD, Mori M. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer 130: 1733–1744, 2012.
69. Takahashi H, Ogata H, Nishigaki R, Broide DH, Karin M. Tobacco smoke promotes lung tumorigenesis by triggering IKKbeta- and JNK1-dependent inflammation. Cancer Cell 17: 89–97, 2010.
70. To Y, Dohi M, Matsumoto K, Tanaka R, Sato A, Nakagome K, Nakamura T, Yamamoto K. A two-way interaction between hepatocyte growth factor and interleukin-6 in tissue invasion of lung cancer cell line. Am J Respir Cell Mol Biol 27: 220–226, 2002.
71. Vlahos R, Wark PA, Anderson GP, Bozinovski S. Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS One 7: e33277, 2012.
72. Wilke CM, Kryczek I, Wei S, Zhao E, Wu K, Wang G, Zou W. Th17 cells in cancer: help or hindrance? Carcinogenesis 32: 643–649, 2011.
73. Wu KC, Yang ST, Hsia TC, Yang JS, Chiou SM, Lu CC, Wu RS, Chung JG. Suppression of cell invasion and migration by propofol are involved in down-regulating matrix metalloproteinase-2 and p38 MAPK signaling in A549 human lung adenocarcinoma epithelial cells. Anticancer Res 32: 4833–4842, 2012.
74. Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, Chiang WF, Wong TY, Shieh DB, Shiau AL, Jin YT, Chen YL. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 7: 311–318, 2009.
75. Xue W, Meylan E, Oliver TG, Feldser DM, Winslow MM, Bronson R, Jacks T. Response and resistance to NF-kappaB inhibitors in mouse models of lung adenocarcinoma. Cancer Discov 1: 236–247, 2011.
76. Ylisirnio S, Hoyhtya M, Turpeenniemi-Hujanen T. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer–TIMP-1 as a prognostic marker. Anticancer Res 20: 1311–1316, 2000.
77. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13: 35–48, 1999.
78. Zhang B, Rong G, Wei H, Zhang M, Bi J, Ma L, Xue X, Wei G, Liu X, Fang G. The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun 374: 533–537, 2008.
79. Zhang Q, Liu S, Ge D, Xue Y, Xiong Z, Abdel-Mageed AB, Myers L, Hill SM, Rowan BG, Sartor O, Melamed J, Chen Z, You Z. Interleu-kin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res 72: 2589–2599, 2012.
80. Zheng S, Chang Y, Hodges KB, Sun Y, Ma X, Xue Y, Williamson SR, Lopez-Beltran A, Montironi R, Cheng L. Expression of KISS1 and MMP-9 in non-small cell lung cancer and their relations to metastasis and survival. Anticancer Res 30: 713–718, 2010.